Afore - Abatacept Versus Adalimumab For Rheumatoid Arthritis In Biologic-Naive Subjects with Background Methotrexate Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 10 years ago on Monday, August 26, 2013, according to the United State Patent & Trademark Office
Word Mark Afore - Abatacept Versus Adalimumab for Rheumatoid Arthritis in Biologic-Naive Subjects with Background Methotrexate
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 85222810
Status Date Monday, August 26, 2013
Filing Date Monday, August 26, 2013
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
BRISTOL-MYERS SQUIBB COMPANY
TRADEMARKS DEPT. - MAILSTOP D33-05
P.O. BOX 4000
PRINCETON NJ 08648-4000

Case File Statements

Disclaimer with Predetermined Text "Abatacept Versus Adalimumab for Rheumatoid Arthritis in Biologic-Naive Subjects with Background Methotrexate"
Goods & Services Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Tuesday, January 25, 2011
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.